|
Patent landscape, scope, and claims: |
Scope and Claims Analysis for US Patent 8,080,580
US Patent 8,080,580 is an incremental but broad chemical-genus patent with layered claim scope: (1) wide coverage of compounds defined by two substitution-variable positions (R1, R2) on Formula (A) or (B), (2) intermediate narrowing via species selections of R1/R2, (3) further narrowing to enumerated stereochemically defined compounds (claims 7 to 9), (4) solid-state coverage via crystals and co-crystals with specific analytical identifiers (claims 10 to 15), and (5) downstream coverage in pharmaceutical compositions and animal treatment methods for obesity and Type 2 diabetes (claims 16 to 20).
The claims are drafted to support both freedom-to-operate (FTO) challenges against alternative analogs (by focusing on R1/R2 substitution options) and defensive IP against solid-form differentiation (by locking in crystallographic and spectroscopic signatures).
What is claimed: compound genus, specific species, and solid forms?
1) Chemical genus in claims 1 (core coverage)
Claim 1 defines a compound of Formula (A) or Formula (B) with:
-
R1 options:
- H
- (C1-C4)alkyl
- (C1-C4)alkoxy
- Cl
- F
- cyano
- fluoro-substituted (C1-C2)alkyl
- (C1-C4)alkyl-SO2— (sulfonyl linkage)
- (C3-C6)cycloalkyl
-
R2 options:
- (C1-C4)alkyl
- (C1-C4)alkoxy
- (C2-C4)alkynyl
- 3-oxetanyloxy
- 3-tetrahydrofuranyloxy
- Cl
- F
- cyano
- fluoro-substituted (C1-C2)alkyl
- (C1-C4)alkyl-SO2—
- (C3-C6)cycloalkyl
- a (C5-C6)heterocycle with 1 or 2 heteroatoms each independently selected from N, O, S
This is a classic “genus-by-substitution” architecture. It is broad because R1 and R2 each independently span multiple substituent classes including heterocycles and alkynyl, while maintaining the same underlying bicyclic core implied by the enumerated stereochemical structures in claims 7 to 9.
2) Genus-to-species narrowing in dependent claims (2 to 6)
- Claim 2 restricts the genus to Formula (A) (not Formula (B)).
- Claims 3 to 6 progressively narrow the enumerated allowed substituent sets:
Claim 3 sets explicit R1 and R2 lists that largely mirror claim 1 but with fewer variants:
- R1: H, methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, F, Cl, cyano, —CF3, cyclopropyl
- R2: methyl, ethyl, propyl, isopropyl, methoxy, ethoxy, F, Cl, cyano, —CF3, —CF2CH3, ethynyl, 3-oxetanyloxy, 3-tetrahydrofuranyloxy, cyclopropyl
Claim 4 further narrows:
- R1: H, methyl, ethyl, isopropyl, methoxy, ethoxy, F, Cl, cyano, —CF3, cyclopropyl
- R2: methyl, ethyl, isopropyl, methoxy, ethoxy, F, Cl, cyano, —CF3, —CF2CH3, ethynyl, 3-oxetanyloxy, 3-tetrahydrofuranyloxy, cyclopropyl
Claim 5 narrows again:
- R1: H, methyl, ethyl, methoxy, ethoxy, F, Cl, cyano, —CF3, cyclopropyl
- R2: methyl, ethyl, methoxy, ethoxy, F, Cl, cyano, —CF3, —CF2CH3, ethynyl, 3-oxetanyloxy, 3-tetrahydrofuranyloxy, cyclopropyl
Claim 6 narrows to a much smaller set:
- R1: methyl, ethyl, F, Cl, cyano, CF3, cyclopropyl
- R2: methoxy or ethoxy
Impact for scope: Claims 1 is the “wide net.” Claims 3 to 6 tighten specific substituent combinations. Claims 7 to 9 then lock in named stereo-specific molecules rather than general substitution language.
What are the enumerated compound species (claims 7 to 9)?
Claims 7 and 9 provide explicit, stereo-defined structures with the same core stereochemical pattern:
- (1S,2S,3S,4R,5S) in claim 7
- (1S,2S,3S,4S,5S) in claim 9
Claim 8 is a single compound.
Claim 8: single explicit compound
A compound that is:
- (1S,2S,3S,4R,5S)-5-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-1-hydroxymethyl-6,8-dioxa-bicyclo[3.2.1]octane-2,3,4-triol
Claim 7: list of (1S,2S,3S,4R,5S) stereoisomers
Claim 7 enumerates 11 compounds spanning variations in:
- benzyl aryl substitution (methoxy, ethoxy, chloro, fluoro)
- phenyl ring substitutions (methyl, fluoro, chloro)
- optional etherified substituents on benzyl aryl ring (oxetan-3-yloxy, tetrahydro-furan-3-yloxy)
These species include (examples):
- (1S,2S,3S,4R,5S)-... 4-methoxy-benzyl ... 4-methyl-phenyl
- (1S,2S,3S,4R,5S)-... 4-ethoxy-benzyl ... 4-methyl-phenyl
- (1S,2S,3S,4R,5S)-... 4-chloro ... 4-methoxy-benzyl
- (1S,2S,3S,4R,5S)-... 4-fluoro ... 4-methoxy-benzyl
- (1S,2S,3S,4R,5S)-... 4-fluoro ... [4-(tetrahydro-furan-3-yloxy)-benzyl]
- (1S,2S,3S,4R,5S)-... [4-(oxetan-3-yloxy)-benzyl] variants
Claim 9: list of (1S,2S,3S,4S,5S) stereoisomers
Claim 9 enumerates 6 compounds that differ from claim 7 mainly by stereochemical assignment at 4-position:
- (1S,2S,3S,4S,5S)-... core
and by substituent set (examples):
- 4-methoxy-benzyl with 4-methyl-phenyl
- 4-ethoxy-benzyl with 4-fluoro-phenyl
- 4-chloro/4-fluoro combinations with methoxy benzyl or unsubstituted benzyl
Impact for competitors: Even if a competitor lands on the same substitution pattern, stereochemistry becomes claim-critical. A stereochemical switch can move the compound out of claims 7/8/9 even if it remains inside the broader Formula (A/B) genus in claim 1 depending on how Formula (A/B) is defined in the patent text.
What is claimed for crystals and co-crystals (claims 10 to 15)?
The solid-form strategy is explicit: claim 10 covers a crystal of formula (4A). Claims 11 to 15 broaden the crystal to include co-formers and specific identity criteria.
Claim 11
- Crystal of claim 10 further comprising L-proline or L-pyroglutamic acid.
Claim 12 (L-pyroglutamic acid; full fingerprint)
Crystal further comprising L-pyroglutamic acid and having one or more of:
- space group: P2(1)2(1)2(1)
- unit cell parameters (substantially equal):
- a = 7.4907(10) Å, α = 90°
- b = 12.8626(15) Å, β = 90°
- c = 28.029(4) Å, γ = 90°
- powder XRD peaks at 2-theta (CuKα, λ = 1.54056 Å):
- 6.4 ± 0.2
- 16.7 ± 0.2
- 17.4 ± 0.2
- 21.1 ± 0.2
- solid-state 13C NMR peak positions (500 MHz; relative to crystalline adamantine 29.5 ppm):
- 16.5 ± 0.2
- 131.1 ± 0.2
- 158.7 ± 0.2
- 181.5 ± 0.2 ppm
Claim 13 (1:1 co-crystal)
- Co-crystal comprising formula (4A) compound and L-pyroglutamic acid in 1:1 stoichiometric ratio.
Claim 14 (reduced fingerprint)
- Crystal with L-pyroglutamic acid having:
- powder XRD: 2-theta 6.4 ± 0.2
- solid-state 13C NMR peaks at:
- 16.5 ± 0.2
- 158.7 ± 0.2
- 181.5 ± 0.2 ppm
Claim 15 (L-proline; separate solid-form set)
Crystal with L-proline and having one or more of:
- space group: C2
- unit cell parameters (substantially equal):
- a = 32.8399(16) Å, α = 90°
- b = 7.2457(4) Å, β = 101.268(5)°
- c = 11.8023(6) Å, γ = 90°
- powder XRD peaks:
- 7.6 ± 0.2
- 12.1 ± 0.2
- 20.3 ± 0.2
- 28.8 ± 0.2
Impact for enforcement: Solid-form claims do not require the full set of identifiers in every dependent claim. They use “one or more” criteria (claims 12 and 15), and reduced fingerprints appear in claims 14. That makes it easier to capture polymorphs or measurement variability, so long as at least one signature matches.
What is claimed for formulations and methods (claims 16 to 20)?
Claim 16: pharmaceutical composition
- pharmaceutical composition comprising:
1) a compound of claims 1 through 9 OR a crystal of claims 10 to 15
2) pharmaceutically acceptable excipient/diluent/carrier
This is a standard formulation claim, but it ties downstream commercialization to both:
- the chemical genus/species (claims 1 to 9)
- and the solid-state forms (claims 10 to 15)
Claim 17: animal treatment for obesity
- method for treating obesity and obesity-related disorders in animals
- administering a therapeutically effective amount of:
- a compound of claims 1 to 9 OR
- a crystal of claims 10 to 15
Claim 18: animal treatment for Type 2 diabetes
- method for treating or delaying progression or onset of Type 2 diabetes
- in animals
- administering therapeutically effective amount of claims 1 to 9 or crystals 10 to 15
Claims 19 and 20: composition-tied treatment methods
- Claim 19: obesity treatment using the pharmaceutical composition of claim 16
- Claim 20: Type 2 diabetes treatment using pharmaceutical composition of claim 16
Impact for patent landscape: If a competitor uses a covered compound but avoids the method claims by restricting to “human-only” language, the animal framing here can still capture veterinary or preclinical dosing in animals. If they use an uncovered polymorph, composition claims still pull them back if the marketed form lands inside claims 10 to 15.
How broad is the scope across the claim stack?
Coverage map
| Claim group |
What it covers |
Scope character |
Key differentiators |
| 1 |
Compound of Formula (A) or (B) with R1/R2 substitution lists |
Broad genus |
Allowed substituent classes for R1 and R2 |
| 2-6 |
Same scaffold, narrower R1/R2 enumerations |
Narrowed genus |
Explicit allowed R1/R2 sets |
| 7-9 |
Explicit stereochemically defined structures |
Exact species |
Stereochemistry at key positions; aryl/benzyl substituents and optional etherified rings |
| 10-15 |
Crystals and co-crystals (L-proline, L-pyroglutamic acid) |
Solid-form scope |
Space group, unit cell, powder XRD peaks, solid-state 13C NMR |
| 16 |
Pharmaceutical composition |
Formulation |
Covered compound/crystal + excipient |
| 17-20 |
Animal treatment methods (obesity, Type 2 diabetes) |
Use scope |
Therapeutic indication and administration of covered compound/composition |
Patent landscape and claim-driven competitive positioning
1) Competitor design-out levers
A competitor trying to avoid US 8,080,580 would focus on one of these claim-exit routes:
2) Enforcement leverage points
From an enforcement standpoint, the strongest hooks are:
- claim 1 genus: multiple substitution classes and heterocycles for R2, with sulfonyl and alkynyl options.
- crystal identity claims: the use of quantitative XRD and NMR peak windows plus space group/unit cell parameters gives a practical evidence template.
- composition claims (16): capture practically any dosage form that uses covered chemical or solid form.
3) Where the landscape is likely tightest
The tightest competitive pinch points are:
- when a competitor uses L-pyroglutamic acid co-crystals with identity falling within claims 12 to 14
- when a competitor uses L-proline co-crystals with identity falling within claim 15
- when a competitor uses the enumerated stereochemical species in claims 7 to 9, regardless of whether they originate as intermediates or final APIs
What to extract from the claims for diligence
For business and litigation-grade diligence, the claim language supports the following workflow:
- Substitution audit against claim 1:
- verify R1 and R2 exact functional classes (including halogens, cyano, CF3 and related fluoro-substituted alkyl, sulfone-linked alkyl, and cycloalkyl/heterocycles)
- Stereochemistry audit against claims 7 to 9:
- confirm absolute configuration at the specified stereocenters
- Solid-state audit for marketed products:
- check co-former identity (L-proline vs L-pyroglutamic acid)
- validate against the powder XRD peak windows and solid-state 13C NMR positions in claims 12, 14, and 15
- check space group/unit cell when listed
- Formulation audit:
- if the API is covered, claim 16 follows for any pharmaceutically acceptable excipient system
- Indication/administration audit:
- method claims apply to “animals,” and composition claims apply regardless of species so long as the compound/crystal is used
Key Takeaways
- US 8,080,580 has a layered structure: a broad genus (claim 1), narrowed substituent lists (claims 3 to 6), stereochemically defined species (claims 7 to 9), and solid-form claims with quantitative XRD/NMR fingerprints (claims 10 to 15).
- The solid-form strategy is built for enforceability: claim 12 and 15 use space group and unit cell, plus powder XRD and solid-state 13C NMR peak windows, and claims 14 reduces the fingerprint set.
- Downstream coverage is comprehensive: composition (claim 16) and animal treatment methods for obesity and Type 2 diabetes (claims 17 to 20) are tied directly to the covered compound and crystal sets.
- The competitive avoidance plan must address at least one axis: R1/R2 substitution, stereochemistry, solid-form/co-crystal identity, or how the product is used/specified (animal treatment).
FAQs
1) Does US 8,080,580 cover both Formula (A) and Formula (B)?
Yes. Claim 1 covers a compound of Formula (A) or Formula (B), while claim 2 narrows to Formula (A).
2) What co-formers drive the crystal claims?
L-proline and L-pyroglutamic acid are explicitly used in claims 11 to 15, with different space group/XRD/NMR fingerprints.
3) Are the solid-form claims tied to specific analytical measurements?
Yes. The claims include quantitative and windowed powder XRD (2-theta) and solid-state 13C NMR peak positions, and in some dependent claims also specify space group and unit cell parameters.
4) Can a competitor avoid infringement by changing the formulation excipient system?
Not if the API is within claims 1 to 9 or the solid form is within claims 10 to 15. Claim 16 captures pharmaceutical compositions that include pharmaceutically acceptable excipients.
5) What therapeutic indications are covered for methods?
Methods are for obesity and obesity-related disorders, and for Type 2 diabetes (treating or delaying onset/progression), in animals, via administration of covered compounds or compositions.
References (APA)
[1] United States Patent 8,080,580.
More… ↓
⤷ Start Trial
|
